遗传性痉挛性截瘫
Hereditary spastic paraplegia
定义 英文原文(暂无中文)
A genetically and clinically heterogeneous group of slowly progressive neurological disorders which in the pure form is characterized by pyramidal signs (weakness, spasticity, brisk tendon reflexes, and extensor plantar responses) predominantly affecting the lower limbs and with possible association of sphincter disturbances and deep sensory loss; and in the complex form by the addition of variable neurological or non-neurological features.
别名
遗传性痉挛性下肢轻瘫
基本事实
- 遗传方式
- 常染色体显性、常染色体隐性、X 连锁隐性
- 发病年龄
- 各年龄段
- 患病率
- 1-9 / 100 000(Europe)
相关基因 60来自下位疾病
Orphanet 未在本条目上直接标注致病基因。下表由本组所属的下位疾病汇总而来,「来源条目」列给出基因实际标注在哪一个 ORPHA 条目上。
| 基因 | 名称 | 来源条目 |
|---|---|---|
| ALDH18A1 | aldehyde dehydrogenase 18 family member A1 | ORPHA:447760 |
| AMPD2 | adenosine monophosphate deaminase 2 | ORPHA:401805 |
| AP5Z1 | adaptor related protein complex 5 subunit zeta 1 | ORPHA:306511 |
| ARL6IP1 | ARL6 interacting reticulophagy regulator 1 | ORPHA:401780 |
| ARSI | arylsulfatase family member I | ORPHA:401815 |
| ATP13A2 | ATPase cation transporting 13A2 | ORPHA:513436 |
| B4GALNT1 | beta-1,4-N-acetyl-galactosaminyltransferase 1 | ORPHA:101006 |
| BSCL2 | BSCL2 lipid droplet biogenesis associated, seipin | ORPHA:100998 |
| C19ORF12 | chromosome 19 open reading frame 12 | ORPHA:320370 |
| CAPN1 | calpain 1 | ORPHA:488594 |
| CCT5 | chaperonin containing TCP1 subunit 5 | ORPHA:139578 |
| CPT1C | carnitine palmitoyltransferase 1C | ORPHA:444099 |
| CYP2U1 | cytochrome P450 family 2 subfamily U member 1 | ORPHA:320411 |
| CYP7B1 | cytochrome P450 family 7 subfamily B member 1 | ORPHA:100986 |
| DDHD1 | DDHD domain containing 1 | ORPHA:101008 |
| DDHD2 | DDHD domain containing 2 | ORPHA:320380 |
| DSTYK | dual serine/threonine and tyrosine protein kinase | ORPHA:101003 |
| ENTPD1 | ectonucleoside triphosphate diphosphohydrolase 1 | ORPHA:401810 |
| ERLIN1 | ER lipid raft associated 1 | ORPHA:401785 |
| ERLIN2 | ER lipid raft associated 2 | ORPHA:209951 |
| FA2H | fatty acid 2-hydroxylase | ORPHA:171629 |
| FARS2 | phenylalanyl-tRNA synthetase 2, mitochondrial | ORPHA:466722 |
| FLRT1 | fibronectin leucine rich transmembrane protein 1 | ORPHA:320406 |
| GBA2 | glucosylceramidase beta 2 | ORPHA:320391 |
| GJC2 | gap junction protein gamma 2 | ORPHA:320401 |
| GPT2 | glutamic--pyruvic transaminase 2 | ORPHA:477673 |
| HACE1 | HECT domain and ankyrin repeat containing E3 ubiquitin protein ligase 1 | ORPHA:464282 |
| HPDL | 4-hydroxyphenylpyruvate dioxygenase like | ORPHA:631076 |
| HSPD1 | heat shock protein family D (Hsp60) member 1 | ORPHA:100994 |
| IBA57 | iron-sulfur cluster assembly factor IBA57 | ORPHA:468661 |
| KIDINS220 | kinase D interacting substrate 220 | ORPHA:521390 |
| KIF1A | kinesin family member 1A | ORPHA:101010 |
| KIF1C | kinesin family member 1C | ORPHA:397946 |
| KIF5A | kinesin family member 5A | ORPHA:100991 |
| KLC2 | kinesin light chain 2 | ORPHA:320406 |
| KPNA3 | karyopherin subunit alpha 3 | ORPHA:171612 |
| KY | kyphoscoliosis peptidase | ORPHA:496689 |
| L1CAM | L1 cell adhesion molecule | ORPHA:2466 |
| MAG | myelin associated glycoprotein | ORPHA:459056 |
| MARS1 | methionyl-tRNA synthetase 1 | ORPHA:401835 |
| MFN2 | mitofusin 2 | ORPHA:64751 |
| MT-ATP6 | mitochondrially encoded ATP synthase membrane subunit 6 | ORPHA:320360 |
| MTRFR | mitochondrial translation release factor in rescue | ORPHA:320375 |
| NIPA1 | NIPA magnesium transporter 1 | ORPHA:100988 |
| NT5C2 | 5'-nucleotidase, cytosolic II | ORPHA:320396 |
| PCYT2 | phosphate cytidylyltransferase 2, ethanolamine | ORPHA:631073 |
| PGAP1 | post-GPI attachment to proteins inositol deacylase 1 | ORPHA:401820 |
| PLP1 | proteolipid protein 1 | ORPHA:99015 |
| PNPLA6 | patatin like domain 6, lysophospholipase | ORPHA:139480 |
| RAB3GAP2 | RAB3 GTPase activating non-catalytic protein subunit 2 | ORPHA:401830 |
| REEP1 | receptor accessory protein 1 | ORPHA:101011 |
| REEP2 | receptor accessory protein 2 | ORPHA:401849 |
| RTN2 | reticulon 2 | ORPHA:100993 |
| SELENOI | selenoprotein I | ORPHA:506353 |
| SLC33A1 | solute carrier family 33 member 1 | ORPHA:171863 |
| SPART | spartin | ORPHA:101000 |
| SPAST | spastin | ORPHA:100985 |
| SPG11 | SPG11 vesicle trafficking associated, spatacsin | ORPHA:2822 |
| SPG14 | spastic paraplegia 14 (autosomal recessive) | ORPHA:100995 |
| SPG16 | spastic paraplegia 16 (complicated, X-linked recessive) | ORPHA:100997 |
近两年的全球研究 975L2
2024/10 起在 Europe PMC 检索所得,按发表时间倒序显示最近 20 篇。标题未译成中文——自动翻译需要接入 LLM 服务,尚未引入。
- 2026-10A De Novo ATP1A3 p.Arg995His Variant in a Patient With an Adult-Onset Primary Lateral Sclerosis-Like Syndrome
- 2026-10病例报告Hereditary Spastic Paraplegia Type 11: A Comprehensive Case Report
- 2026-09综述Hereditary spastic paraplegia: a practical approach
- 2026-09Serine palmitoyltransferase (SPT) inhibition in SPTSSA-related complex hereditary spastic paraplegia
- 2026-09开放获取Subtle hypometabolism on [<sup>18</sup>F]FDG-PET, yet absent [<sup>123</sup>I]FP-CIT SPECT binding in a patient with spastic paraplegia type 7
- 2026-09开放获取Hereditary and Non-hereditary Cerebellar Ataxias in Latvia: Six Years of Experience at the National Reference Centre (ERN-RND Affiliated Partner)
- 2026-09综述Adaptor protein complex 5 (AP-5) and the SPG11-SPG15 coat-like machinery in endolysosomal retrograde trafficking and human disease: A review
- 2026-09病例报告开放获取A Novel KCNA1 Variant in a Patient With Tremor and Autism Spectrum Disorder Causes Mixed LOF/GOF Defects of Kv1.1 Channels
- 2026-09综述Phenotypic Spectrum and Clinical Approach to Early-Onset Hereditary Spastic Paraplegia
- 2026-09Defective ATP13A2-ITCH-ALIX signaling impairs intraluminal vesicle biogenesis and increases neuronal vulnerability
- 2026-09病例报告Expanding the adult spectrum of TUBB4A disease: a spasticity-tremor phenotype with network imaging correlates
- 2026-09开放获取Spectrum of Hereditary Ataxia in Omani Children
- 2026-09开放获取Cholesterol maintains the degradative capacity of lysosomes during clearance and recycling of dysfunctional mitochondria
- 2026-09Localized disruption of the presynaptic endoplasmic reticulum in Atlastin mutants
- 2026-09系统综述综述病例报告开放获取Progressive Spastic Paraparesis Caused by Thoracic Spinal Epidural Lipomatosis: A Case Report and Systematic Review
- 2026-09综述Lipid flip-flop in biological membranes: through the lens of TMEM16F
- 2026-09病例报告"Ears of the lynx" sign on MRI: A radiologic clue to hereditary spastic paraplegia
- 2026-09病例报告开放获取“Ears of the lynx” sign on MRI: A radiologic clue to hereditary spastic paraplegia
- 2026-09开放获取Multivariate Characterization of Gait Variability Under Simulated Ship Roll Motion
- 2026-09病例报告Cognitive impairment as a manifestation of SPG7: case report
境外已获批用于本病的药物 0L2
欧盟与美国均未检索到已获批用于本病的药物。
尚未获批的在研药物(1 项)
这些药已被欧盟或美国的监管机构认定为罕见病用药(英文 orphan drug designation,中文行业里通称「孤儿药资格」——「孤儿」说的是这类药市场太小、没有厂商愿意认领,不是在说病人)。但这只是一种监管身份:意味着监管机构给予研发上的激励,不代表这个药已被证明有效,也不代表将来一定能上市,绝大多数最终不会成药。列在这里是为了看清有哪些方向正在被尝试。
- adeno-associated virus serotype 9 gene transfer vector expressing huma美国2021-02-16Treatment of hereditary spastic paraplegia 47官方记录
数据来自欧洲药品管理局(EMA)的药品与罕见病用药资格公开导出表,以及美国 FDA 的罕见病用药资格数据库(Orphan Drug Product Designation Database)。两边口径不同:欧盟一侧取的是当前状态仍为「已授权」的药品;美国一侧记录的是「曾获批准」这一事实,FDA 的公开表不追踪药物此后是否退市(例如 Relyvrio 于 2024 年撤市,表中仍记为已获批)。请以官方记录页为准。
在中国开展的临床试验 5L2
按病名在 ClinicalTrials.gov 检索、并校验研究中心含中国大陆而来。登记状态不等于现在真的能入组——务必按 NCT 号到原站核实,并与主治医生商量。
登记为可入组 3
- 招募中NCT06478238Calcium Folinate Treatment of Spastic Paraplegia 56中国研究中心 1 个:Shanghai
- 招募中NCT06844734A Prospective Cohort Study of ITB Treatment for HSP中国研究中心 1 个:Shanghai
- 招募中NCT06936163A Prospective Cohort Study of Surgical Treatment for Foot Deformities in HSP中国研究中心 1 个:Shanghai
其他状态的试验(2 项)
- 状态未知NCT04101643PCSK9 Inhibitor Treatment for Patients With SPG5中国研究中心 1 个:Fuzhou
- 状态未知NCT05196178Spinal Cord Stimulation Therapy for Hereditary Spastic Paraplegias Patients中国研究中心 1 个:Beijing
中国境外的在招试验 22L2
这些试验在中国没有研究中心,通常无法直接报名——入组一般要求在当地居住并接受随访。列在这里是因为它另有用处:看清楚全世界正在试哪些药、做到了哪一期、由谁在做。把药名和 NCT 编号记下来去问主治医生,或据此进一步查该药是否已在境外获批、是否有拓展性用药(expanded access)通道。
CT.gov 报告命中 22 项,此处取回并展示最近的 15 项。
- 招募中NCT07417943Neuromodulation to Enhance Motor Function in HSP美国
- 招募中NCT06692712Phase 3 Efficacy Study With Concurrent Control of IT MELPIDA in SPG50.Concurrent Controls.西班牙、美国
- 招募中NCT07478172Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease美国
- 尚未开始招募NCT06948019Safety and Efficacy of AAV9/AP4B1 (BFB-101) For Patients With AP4B1-related Hereditary Spastic Paraplegia Type 47 (SPG47)美国
- 招募中NCT06742697Flexibility, Resistance, Aerobic, Movement Execution Training in Adults With Hereditary Spastic Paraplegia意大利
- 招募中NCT07798674TreatHSP Platform: Adaptive Natural History Platform for Ataxias, HSPs, and Spastic Ataxias奥地利、捷克、法国、德国、爱尔兰、意大利、荷兰、波兰 等 9 国
- 招募中NCT06553976Spastic Paraplegia - Centers of Excellence Research Network美国
- 招募中NCT06229626Evaluation of an Intensive Training Program for Patients with Hereditary Spastic Paraparesis SPG4/Spast法国
- 招募中NCT07136844Gait Analysis Parameter and Upper Limb Evaluation in Adult Patients With Neurological or Metabolic Pathology比利时
- 招募中NCT06572046STOP-HSP.Net: a Registry for Hereditary Spastic Paraplegia as an Integration Tool for Future Therapeutic Strategies意大利
- 招募中NCT06092346A Natural History Study Seeks to Understand the Clinical, Genomic, Pharmacological, Laboratory, and Dietary Determinates of Pyrimidine and Purine Metabolism Disorders美国
- 招募中NCT05848271Natural History Study of Patients with HPDL Mutations美国
- 招募中NCT07090057The Effect of Targeting the Plantaris Muscle-tendon in Surgical Correction of Ankle Equinus in Children加拿大
- 招募中NCT05518188Melpida: Recombinant Adeno-associated Virus (Serotype 9) Encoding a Codon Optimized Human AP4M1 Transgene (hAP4M1opt)美国
- 招募中NCT05354622Hereditary Spastic Paraplegia Genomic Sequencing Initiative (HSPseq)美国
外部标识与链接
发现这一页有错误?告诉我 · 邮件主题会自动带上本页的 ORPHA 编号
本页数据来源
- 疾病定义、同义词、基因、表型、流行病学:Orphanet(CC BY 4.0)
- 中文病名:Orphanet 中文包,冻结于 2020-06-01
- 表型中文标签:HPO 简体中文翻译(CHPO 上游成果)